UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

The New England journal of medicine, 2017-03, Vol.376 (10), p.917-927

2017

Volltextzugriff (PDF)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

Ecancermedicalscience, 2016-09, Vol.10, p.676-676

2016

Volltextzugriff (PDF)

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Volltextzugriff (PDF)

Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome

Journal of immunotherapy (1997), 2011-06, Vol.34 (5), p.419-427

2011

Volltextzugriff (PDF)

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8581-8581

2011

Volltextzugriff (PDF)

A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8546-8546

2011

Volltextzugriff (PDF)

A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3082-3082

2010

Volltextzugriff (PDF)

MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13112-e13112

2010

Volltextzugriff (PDF)

Phase I evaluation of an 18-day outpatient IL-2 infusion following AC+t adjuvant chemotherapy of loco-regionally advanced breast cancer (BrCA)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e11051-e11051

2010

Volltextzugriff (PDF)

Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain

Journal of immunological methods, 2009-09, Vol.349 (1), p.45-55

2009

Volltextzugriff (PDF)

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Leukemia, 2009-06, Vol.23 (6), p.1054-1061

2009

Volltextzugriff (PDF)

A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.9056-9056

2009

Volltextzugriff (PDF)

Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5034-5034

2009

Volltextzugriff (PDF)

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Cancer, 2009-02, Vol.115 (3), p.551-560

2009

Volltextzugriff (PDF)

Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.9022-9022

2008

Volltextzugriff (PDF)

Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5051-5051

2008

Volltextzugriff (PDF)

Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.9066-9066

2008

Volltextzugriff (PDF)

Prolonged survival in objective responders to ipilimumab therapy

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20004-20004

2008

Volltextzugriff (PDF)

Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice

Journal of immunotherapy, 2008-05, Vol.31 (4), p.325-333

2008

Volltextzugriff (PDF)

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Blood, 2008-04, Vol.111 (8), p.4022-4028

2008

Volltextzugriff (PDF)

Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)—SWOG S0317

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15516-15516

2007

Volltextzugriff (PDF)

A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.8538-8538

2007

Volltextzugriff (PDF)

ReGel(R) Polymer-based Delivery of Interleuldn-2 as a Cancer Treatment

Journal of immunotherapy, 2006-10, Vol.29 (5), p.524-535

2006

Volltextzugriff (PDF)

Phase I/II trial of Amplimexon (imexon, inj.) plus dacarbazine in patients with stage III or IV malignant melanoma

Melanoma research, 2006-09, Vol.16 (Supplement 1), p.S86

2006

Volltextzugriff (PDF)

Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy na??ve patients with metastatic melanoma

Melanoma research, 2006-09, Vol.16 (Supplement 1), p.S78

2006

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(109)

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases

A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma

A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle

MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients

Phase I evaluation of an 18-day outpatient IL-2 infusion following AC+t adjuvant chemotherapy of loco-regionally advanced breast cancer (BrCA)

Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331)

Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine

Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317

Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma

Prolonged survival in objective responders to ipilimumab therapy

Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)—SWOG S0317

A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma

ReGel(R) Polymer-based Delivery of Interleuldn-2 as a Cancer Treatment

Phase I/II trial of Amplimexon (imexon, inj.) plus dacarbazine in patients with stage III or IV malignant melanoma

Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy na??ve patients with metastatic melanoma

Suchergebnisse filtern